US5830910A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders
Assignee: KENTUCKY RESEARCH FOUNDATIONS, University of
•
Filing: 1995-10-23
•
Granted: 1998-11-03
•
Expires: 2015-10-23
Abstract
Abstract The present invention relates to novel therapeutic uses of certain compounds to protect nerve cells from injury and death. The compounds include cytochalasin D and related analogs, and cytochalasin E and related analogs.
Inventors
- 👤 Mark P. Mattson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 22:52
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/407; A61K31/403
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
138 words
A method for reducing adverse effects of a neurodegenerative disorder comprising: administering to a patient a therapeutically effective amount of at least one compound selected from the group consisting of compounds represented by Formulas (I)-(II) and their pharmaceutically acceptable salts: ##STR9## where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 represent hydrogen, C 1 to C 6 alkyl or hydroxy, or where R 3 and R 4 together represent a carbonyl group; or ##STR10## where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 represent hydrogen, C 1 to C 6 alkyl, hydroxy, or OAC, or where R 3 and R 4 together represent a carbonyl group.
Claim 2
Independent Claim
138 words
A method for reducing adverse effects of a neurodegenerative disorder comprising: administering to a patient a therapeutically effective amount of at least one compound selected from the group consisting of compounds represented by Formulas (I)-(II) and their pharmaceutically acceptable salts: ##STR9## where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 represent hydrogen, C 1 to C 6 alkyl or hydroxy, or where R 3 and R 4 together represent a carbonyl group; or ##STR10## where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 represent hydrogen, C 1 to C 6 alkyl, hydroxy, or OAC, or where R 3 and R 4 together represent a carbonyl group.
Claim 3
Dependent Claim
19 words
A method according to claim 1, wherein the compound is represented by formula (I) or pharmaceutically acceptable salts thereof.
Claim 4
Dependent Claim
12 words
A method according to claim 2, wherein the compound is cytochalasin D.
Claim 5
Dependent Claim
19 words
A method according to claim 1, wherein the compound is represented by formula (II) or pharmaceutically acceptable salts thereof.
Claim 6
Dependent Claim
12 words
A method according to claim 4, wherein the compound is cytochalasin E.
Claim 7
Dependent Claim
51 words
A method according to claim 1, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, Down's syndrome, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, cerebral ischemia, cerebral infarction, thromboembolic and hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, pulmonary surgery, and cerebral trauma.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-11-02 | 2002-05-04 | 2002-11-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-11-02 | 2006-05-04 | 2006-11-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-11-02 | 2010-05-04 | 2010-11-03 | $7700.00 | Window Closed / Lapsed |